DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

Phase 1

Terminated

Conditions: Myelofibrosis

Interventions: Drug: Idelalisib
Drug: Ruxolitinib

First Posted Date: 2015-05-06

Last Posted Date: 2020-09-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 10

Registration Number: NCT02436135

Locations: 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2015-04-10

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 111

Registration Number: NCT02413593

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

Phase 1

Completed

Conditions: Long QT Syndrome

Interventions: Drug: Eleclazine

First Posted Date: 2015-04-08

Last Posted Date: 2019-07-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 49

Registration Number: NCT02412098

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Drug: Andecaliximab
Drug: Placebo

First Posted Date: 2015-04-01

Last Posted Date: 2019-04-23

Lead Sponsor: Gilead Sciences

Target Recruit Count: 187

Registration Number: NCT02405442

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

and more 69 locations

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 1

Terminated

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Entospletinib
Drug: Vincristine
Drug: Dexamethasone
Drug: CNS Prophylaxis

First Posted Date: 2015-03-31

Last Posted Date: 2020-01-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 30

Registration Number: NCT02404220

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇩🇪
Medizinische Klinik und Poliklinik I, Wurzburg, Germany

and more 10 locations

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: Voxilaprevir

First Posted Date: 2015-03-30

Last Posted Date: 2020-03-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 20

Registration Number: NCT02402452

Locations: 🇩🇪
APEX GmbH, München, Germany
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Texas Liver Institute, San Antonio, Texas, United States

and more 1 locations

Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function

Phase 1

Completed

Conditions: HIV

Interventions: Drug: Bictegravir

First Posted Date: 2015-03-27

Last Posted Date: 2019-10-11

Lead Sponsor: Gilead Sciences

Target Recruit Count: 19

Registration Number: NCT02400307

Locations: 🇺🇸
Avail Clinical Research, DeLand, Florida, United States
🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

and more 4 locations

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Phase 2

Completed

Conditions: HIV-1 Infection

Interventions: Drug: BIC
Drug: F/TAF
Drug: DTG
Drug: DTG Placebo
Drug: BIC Placebo
Drug: B/F/TAF

First Posted Date: 2015-03-25

Last Posted Date: 2020-04-07

Lead Sponsor: Gilead Sciences

Target Recruit Count: 98

Registration Number: NCT02397694

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: Voxilaprevir

First Posted Date: 2015-03-25

Last Posted Date: 2020-04-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 33

Registration Number: NCT02397707

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇳🇿
Auckland Clinical Studies, Auckland, New Zealand
🇺🇸
Texas Liver Institute, San Antonio, Texas, United States

and more 1 locations

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Phase 1

Completed

Conditions: Solid Tumors and Lymphomas

Interventions: Drug: Alobresib
Drug: Exemestane
Drug: Fulvestrant

First Posted Date: 2015-03-19

Last Posted Date: 2020-12-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 33

Registration Number: NCT02392611

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy